As regulatory expectations evolve, comprehensive genomic characterization is becoming increasingly important for advanced therapeutics. Join Oxford Nanopore to discuss recent FDA guidance, the expanding role of long-read sequencing in genomic QC, and key applications across cell and gene therapy development.

Key Topics:

• FDA guidelines and implications for genomic characterization
• Long-read sequencing applications for cell lines, genome edits, plasmids, and viral vectors
• Enabling deeper genomic insights with Oxford Nanopore to support quality and regulatory readiness

Date: Tuesday, July 28, 2026
Time: 1:00-2:00 PM EST
Location: Zoom (link to be provided upon registration)

 

SPEAKERS

Mia Rapoza Peterson

Strategic BioPharma Manager

Oxford Nanopore Technologies

Namita Damle

Field Applications Scientist

Oxford Nanopore Technologies